东亚药业股价涨7.02%，诺安基金旗下1只基金位居十大流通股东，持有81.17万股浮盈赚取114.45万元

Group 1 - East Asia Pharmaceutical Co., Ltd. experienced a stock price increase of 7.02%, reaching 21.49 CNY per share, with a trading volume of 4.82 million CNY and a turnover rate of 0.20%, resulting in a total market capitalization of 2.465 billion CNY [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The main revenue composition includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional (supplementary) products (4.46%) [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares, with an estimated floating profit of approximately 1.1445 million CNY [2] - The Noan Multi-Strategy Mixed A fund was established on August 9, 2011, with a current scale of 1.855 billion CNY, achieving a year-to-date return of 5.21% and a one-year return of 88.18% [2] - The fund manager, Kong Xianzheng, has a tenure of 5 years and 50 days, with the fund's total asset size at 5.608 billion CNY, achieving a best return of 93.39% and a worst return of -16.74% during his tenure [3]